1) Is a membrane filtration method for validation of bioburden in
disinfectant solutions covered by the 'membrane filtration methods' in
the European and United States Pharmacopoeia?
2) Which environmental isolates would we challenge the method with if
our production environment surface contact plates very rarely show
growth? Is it acceptable to use only the organisms listed as for bulk
bioburden methods in the EP/USP?
on behalf of Pharmig
The PMFList (http://microbiol.org/PMFList_info.htm) is operated from
The Microbiology Network (http://microbiol.org) and supported by
our sponsors (http://microbiol.org/sponsor.htm) as a service to
the scientific community.